Related Experiment Video
Updated: Apr 12, 2026

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma
Published on: January 25, 2015
Hepatic angiosarcoma may have fair survival nowadays
Neng-Chyan Huang1, Yau-Chang Kuo, Jui-Chin Chiang
1From the Department of Emergency Medicine, Kaohsiung Veterans General Hospital, Kaohsiung (N-CH, Y-MH, Y-TC, S-RW, H-TC); National Yang-Ming University, School of Medicine, Taipei (N-CH, H-MW, Y-MH, Y-TC, S-RW, H-TC, J-SW); Department of Environmental and Occupational Health, College of Medicine, National Cheng Kung University, Tainan (N-CH, J-CC, H-RG); Department of Occupational and Environmental Medicine, National Cheng Kung University and National Cheng Kung University Hospital, Tainan (Y-CK, H-RG); Department of Family Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung (J-CC); Department of Occupational Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung (J-CC); Division of Nephrology, Department of Internal Medicine, E-Da Hospital, Kaohsiung (S-YH); Department of Health Management, I-Shou University, Kaohsiung (S-YH); Division of Gastroenterology, Department of Internal Medicine, Kaohsiung Veterans General Hospital, Kaohsiung (H-MW); Department of Health Care and Management, Yuh-Ing Junior College of Health Care and Management, Kaohsiung (Y-TC); Department of Pathology, Kaohsiung Veterans General Hospital, Kaohsiung (J-SW); Department of Radiation Oncology, Sin-Lau Christian Hospital, Tainan (S-YH); Department of Radiation Oncology, Chi Mei Liouying Hospital, Tainan (S-YH); and Department of Nursing, Chang Jung Christian University, Tainan, Taiwan (S-YH).
Hepatic angiosarcoma (HAS) survival may be improving. Combination treatments like surgery and chemotherapy show promise for long-term outcomes in rare liver cancer patients.
Area of Science:
- Hepatology
- Oncology
- Surgical Pathology
Background:
- Hepatic angiosarcoma (HAS) is a rare and aggressive primary liver cancer.
- Historically, HAS has had a poor prognosis with very low long-term survival rates.
Observation:
- A retrospective study in Taiwan (2000-2010) identified 9 HAS cases.
- 33.3% of these patients survived for 2 years or more.
- Literature review identified additional HAS cases with prolonged survival, some without surgery.
Findings:
- Survival rates for HAS appear to be improving.
- Long-term survival was observed in patients treated with surgery and adjuvant chemotherapy.
- Chemotherapy alone also demonstrated potential for fair survival in some cases.
Implications:
- Modern treatment combinations may offer better prognoses for HAS patients.
- Further research into neoadjuvant and adjuvant therapies is warranted.
- This study highlights the potential for improved outcomes in rare liver cancers.

